Get Connected:


Latest News

Multiple Sclerosis Drug Shown to Slow Disability Progression
Gilenya (fingolimod) can slow disability progression in patients with relapsing remitting multiple sclerosis.
More than 600 lots of products recalled by Wells Pharmacy Network.
The American Academy of Pediatrics urges cessation of codeine use in children due to severe risks.
Top news of the day from across the healthcare landscape.
Research improves projection of multiple sclerosis disease progression.
Memantine and donepezil hydrochlorides (Namzaric) extended-release capsules in four dosage strenghts are now available by prescription at US pharmacies.
CMS releases Medicare premium and cost data for 2017.
Trial shows no increased incidence of adverse events or any new safety signals with exposure to Otezla.
View More >

From the Journals

This study examines variations in overall use, and potentially inappropriate use, of non-warfarin direct-acting oral anticoagulants across sites within the Veterans Health Administration.
Individuals with treatment-resistant depression do not achieve and sustain remission after multiple pharmacotherapies, with an unknown impact on employment. This study investigates the expenditures of TRD from a private-payer perspective in Canada.
This study highlights the implications of noncompliance with the use of in-network providers for immunization services, shedding light on value-based benefits design to promote access to recommended vaccinations.
Specialty-focused partial-fill plan designs are gaining traction, with conflicting opinions on whether they reduce waste or impact the quality of care.
This study seeks to determine the economic effects of warfarin discontinuation in patients with nonvalvular atrial fibrillation.
This study evaluates whether provider adoption and use of formulary decision support for e-prescribing are directly associated with significant prescriber and patient behavior change.
The development and implementation of a rare disease management program by healthcare providers and payors could greatly assist in improving the clinical, psycho-social and economic impacts for this patient population.   
Upcoming Partner Events